Rallybio
Rallybio develops therapies for rare diseases, with a diversified portfolio and multinational clinical trials.
Company Overview
Rallybio is a biotechnology company dedicated to developing therapies for rare diseases. The company has established a robust portfolio of product candidates and is engaged in conducting multinational clinical trials. Headquartered in New Haven, CT, with an additional location in Farmington, CT, Rallybio collaborates with leading academic clinical centers and industry leaders worldwide.
Products
Rallybio's product pipeline focuses on addressing rare diseases in several medical domains. Key clinical-stage products include RLYB212, aimed at preventing Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), RLYB116, a C5 inhibitor for complement dysregulation diseases, and RLYB114 targeting ophthalmic diseases through C5 inhibition. The company also has a preclinical candidate, RLYB331, for treating anemia associated with iron overload disorders.
Therapeutic Focus Areas
Rallybio's pipeline targets several areas of rare disease medicine including hematology, immuno-inflammation, maternal fetal health, ophthalmology, and metabolic disorders. The company's diversified approach enables the development of treatments for a wide range of conditions, thereby broadening its impact on the rare disease therapeutic landscape.
ENPP1 Program
Rallybio's ENPP1 Program is focused on developing a small molecule inhibitor for the treatment of Hypophosphatasia (HPP). This initiative represents a key aspect of the company's efforts to address metabolic bone disorders and expand its therapeutic approach into enzyme-targeted treatments.
Collaborations
Rallybio collaborates with academic clinical centers and industry leaders worldwide to advance its mission of developing therapies for rare diseases. These partnerships are vital in supporting the research and clinical development necessary to bring innovative treatments to market and improve patient outcomes globally.
